Belite Bio Inc
BLTEHealthcare|Biotechnology|USA
$149.25
-3.91 (-2.55%)
Tangible Book
$19.85
About
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Stock Price
+140.6%(1Y)
Pipeline Summary
7 total trials4
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
Active: 2Completed: 5
Active Trials (2)
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
NCT06388083STGD1
Phase 2Phase 3Active
Enrollment: 60 participants
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
Phase 3Active
Enrollment: 429 participants
BioScore
4.9/10
Cautious
Ownership
Recent Insider Trades
Scholl Hendrik PeterSELL
2026-06-1810,000 shares @ $145.24
Scholl Hendrik PeterSELL
2026-06-1610,000 shares @ $140.57
MATA NATHAN L.SELL
2026-05-07666 shares @ $153.21
MATA NATHAN L.SELL
2026-05-061,000 shares @ $153.84
MATA NATHAN L.SELL
2026-05-051,000 shares @ $155.5
Recent News
2026-06-15 12:30:34
2026-06-14 20:52:01
Data last updated: Jul 13, 2026, 12:39 PM